Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

Audio summary from the New England Journal of Medicine — NEJM This Week — July 3, 2025 ...

DESTINY-Lung04 phase 3 trial of Enhertu initiated in patients with previously untreated HER2 mutant metastatic non-small cell lung cancer. News release. Daiichi Sankyo. December 23, 2021.

A 63-year-old woman was evaluated for dyspnea and edema. Soft-tissue thickening was noted in the retroperitoneum and mediastinum and around the heart and vessels. A diagnosis was made.

AstraZeneca and Daiichi Sankyo have earned their second FDA approval for Datroway, scoring a nod for the drug to treat EGFR-mutated non-small cell lung cancer.

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...